Effectiveness and Tolerability of Anthracycline vs NonAnthracycline Neoadjuvant Chemotherapy Regimens with dual HER2 blockade in HER2 positive Early Breast Cancer Treatment

被引：0
|
作者：
Gudelj, D. [1 ]
Cular, K. [1 ]
Dakovic, A. -m. [1 ]
Barta, L. [2 ]
Koren, L. [2 ]
Koren, A. [2 ]
Krizic, M. [1 ]
Popovic, M. [1 ,2 ]
Plavetic, N. Dedic [1 ,2 ]
Silovski, T. [1 ,2 ]
机构：
[1] Univ Hosp Ctr Zagreb, Dept Oncol, Zagreb, Croatia
[2] Univ Zagreb, Sch Med, Zagreb, Croatia
来源：
BREAST | 2025年 / 80卷
关键词：
D O I：
10.1016/j.breast.2025.104061
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P218
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
    Advani, Pooja
    Cornell, Lauren
    Chumsri, Saranya
    Moreno-Aspitia, Alvaro
    BREAST CANCER-TARGETS AND THERAPY, 2015, 7 : 321 - 335
  • [2] Dual HER2 blockade in adjuvant and neoadjuvant treatment of HER2-positive breast cancer: the role of pertuzumab
    Duchnowska, Renata
    ONCOLOGY IN CLINICAL PRACTICE, 2018, 14 (01): : 43 - 47
  • [3] Sparing chemotherapy with dual HER2 blockade in combination with endocrine therapy for advanced HER2 positive breast cancer
    Werutsky, Gustavo
    Reinert, Tomas
    Fay, Andre Poisl
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S573 - S576
  • [4] Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer
    Mattos, Bruna RaphaeliSilva
    Cesca, Marcelle Goldner
    Leite, Luciana de Moura
    Tavares, Monique Celeste
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla AlbinaZanco
    Silva, Erick Figueiredo
    Rocha, Francisca Giselle
    Loose, Simone Klug
    Campos, Fernando AugustoBatista
    Sanches, Solange Moraes
    de Lima, Vladmir ClaudioCordeiro
    Ponde, Noam Falbel
    CANCER RESEARCH, 2021, 81 (04)
  • [5] Prognostic significance and evolution of HER2 zero, HER2 low and HER2 positive in breast cancer after neoadjuvant treatment
    Wei, T.
    Wang, D.
    Peng, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S301 - S302
  • [6] Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)
    Gonzalez-Santiago, Santiago
    Saura, Cristina
    Ciruelos, Eva
    Luis Alonso, Jose
    de la Morena, Pilar
    Santisteban Eslava, Marta
    Gallegos Sancho, Maria Isabel
    de Luna, Alicia
    Dalmau, Elsa
    Servitja, Sonia
    Ruiz Borrego, Manuel
    Ignacio Chacon, Jose
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 184 (02) : 469 - 479
  • [7] Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)
    Santiago González-Santiago
    Cristina Saura
    Eva Ciruelos
    José Luis Alonso
    Pilar de la Morena
    Marta Santisteban Eslava
    Maria Isabel Gallegos Sancho
    Alicia de Luna
    Elsa Dalmau
    Sonia Servitja
    Manuel Ruiz Borrego
    José Ignacio Chacón
    Breast Cancer Research and Treatment, 2020, 184 : 469 - 479
  • [8] HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer
    Yao, L.
    Liu, Y.
    Li, Z.
    Ouyang, T.
    Li, J.
    Wang, T.
    Fan, Z.
    Fan, T.
    Lin, B.
    Xie, Y.
    ANNALS OF ONCOLOGY, 2011, 22 (06) : 1326 - 1331
  • [9] Is HER2 loss after neoadjuvant chemotherapy determinant for the choice of adjuvant treatment in HER2 positive breast cancer patients?
    Altundag, Kadri
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (02) : 328 - 328
  • [10] Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
    Zheng-Jun Yang
    Fei Xin
    Zu-Jin Chen
    Yue Yu
    Xin Wang
    Xu-Chen Cao
    BMC Cancer, 24
12345